drugset
drugset / Trial / NCT01129856

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

NCT01129856 ↗

Phase 3 Completed 198 enrolled Eyegate Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.

Timeline

Start
2010-06
Primary completion
2011-01
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule — Other

Indications

dry eye syndrome